Monday, June 16, 2025

Latest

PharmaTher Partners With TSRL For Microneedle Patch Development

PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The arrangement will see the two firms jointly develop a microneedle array patch focused on the incorporation of psychedelics, such as ketamine, psilocybin, DMT, MDMA, and LSD, as well as antiviral medications.

TSRL is a firm focused on developing microneedle patches that targets the delivery of antivirals for the treatment of influenza. Together, the firms will look to control the manufacturing and supply of patches for clinical and commercial drug programs being undertaken by both companies.

The patch to be used is based on tech licensed from Queens University of Belfast, with the resulting product to be focused on improving safety, efficacy, and compliance of compounds that currently are not delivered via such tech. Instead, psychedelic and antiviral compounds are commonly delivered orally, intravenously, inhaled, or injected.

“We are very excited to collaborate with TSRL as they have de-risked certain technical and manufacturing aspects of the microneedle patch and by sharing our resources it will allow PharmaTher to expedite the clinical and commercial development of the microneedle patch with ketamine and other psychedelics. Also, the collaboration will ensure control over the manufacturing and supply of microneedle patches for not only both of our respective product programs, but also it may unlock future commercial partnering opportunities with pharmaceutical companies seeking a microneedle patch delivery system.”

Fabio Chianelli, CEO of PharmaTher

TSRL thus far has successfully conducted pre-IND meetings with the US FDA, for which it has come to an agreement with the firm for their product development plans. The company is currently classified as a pre-clinical accelerator for anti-infective therapeutic product concepts.

PharmaTher last traded at $0.28 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

First Majestic Silver: The Santa Elena Mine

Equinox Gold: Guidance Cut After Issues At Greenstone

Simply Solventless Q4 Earnings: So Much For Guidance

Recommended

NexGen Energy Receives Approval For Site Expansion At Rook I Project

ESGold Sees Installation Of Humphrey Spirals Completed At Montauban

Related News

Pharmather Appoints Dr Alberto J Espay As Scientific Advisor

Pharmather Inc (CSE: PHRM) has appointed a prolific Parkinson’s researcher to its team of scientific...

Wednesday, November 11, 2020, 08:29:13 AM

PharmaTher Files With FDA For Orphan Drug Designation In Use Of Ketamine For ALS

PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA...

Tuesday, May 25, 2021, 09:00:24 AM

PharmaTher To Commence Phase 2 Clinical Study On Ketamine In Q2 2021

Pharmather Inc (CSE: PHRM) is successfully progressing on the development of its proposed phase 2...

Thursday, February 4, 2021, 08:28:04 AM

Revive Therapeutics, Pharmather Partner On Psilocybin Cancer Research

Revive Therapeutics (CSE: RVV) and Pharmather Inc (CSE: PHRM) this morning jointly announced a research...

Wednesday, November 18, 2020, 07:30:40 AM

PharmaTher Collaborates For Research On Psychedelic Microdosing Tech

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related...

Tuesday, February 23, 2021, 07:25:33 AM